Butterfly Network Q2 2026: Growth in the Embedded AI Wing, Revenue Up, EPS Watch List Expands

Headline numbers that matter

Butterfly Network, Inc. (NYSE: BFLY) reported for the quarter ended June 30, 2026:

• Total revenue: $32.6 million, up 39% from $23.4 million in the year-ago quarter.
• U.S. revenue: $27.6 million, up 57% year over year.
• Gross margin: 71%, up 770 basis points versus the prior year.
• Adjusted EBITDA: negative, i.e., an adjusted EBITDA loss that the company frames as above guidance.

Note: The release emphasizes revenue and gross margin progress while still highlighting an Adjusted EBITDA loss. The company also said it has raised its full-year revenue forecast and improved EPS consensus expectations for the period, though actual EPS figures aren’t provided in this release.

A platform story, not a hardware anecdote

The core narrative remains: Butterfly is positioning its Ultrasound-on-Chip platform as a hub for an expanding software ecosystem. The Embedded portfolio grew to 11 partners with the addition of Midjourney and Aleph Neuro, underscoring a push to monetize through co-developed AI-enabled applications. Two Embedded partners demonstrated entirely new uses built atop the Butterfly platform, signaling a shift from hardware throughput to an integrated, software-forward growth engine.

Operational highlights and partnerships

• Embedded partnerships: two new deployments of AI-enabled applications and a move toward broader co-development with partners such as Midjourney and Aleph Neuro.
• Compass AI and Enterprise Momentum: six new enterprise software agreements, expanding the software pipeline year over year.
• FedRAMP progress: provisional authorization to sell across the U.S. Department of Veterans Affairs, with certification targeted in Q3 2026.
• Medical Education Expansion: four additional medical education partners in the quarter; long-term strategic partnership with VCOM to support physician development and practice insights.
• Butterfly Garden: added a partner focused on precision needle-guidance AI; three existing tools expected to be commercially available by year-end.
• Home & Community Care: first commercial implementation planned in H2 2026, with revenue expected in Q4.
• International Expansion: regulatory authorization in Brazil, opening access to a large, fast-growing ultrasound market.

What the results portend for Butterfly and sector peers

Butterfly’s Q2 narrative fits a broader trend: hardware-enabled medical devices increasingly monetized through software, services, and ecosystem partnerships. The 71% gross margin suggests meaningful margin leverage as software and embedded solutions scale, even as the company remains in a growth phase with an adjusted EBITDA loss that management frames as a temporary candor rather than a chronic condition.

For peers, two takeaways loom large. First, platform strategies that fuse device capability with AI-driven software can unlock faster top-line growth and better gross margins, particularly when a robust partner network is in place. Second, regulatory and government channels, exemplified by FedRAMP progress, may become significant revenue streams for AI-enabled health-tech players, improving visibility and contract durability beyond direct hospital purchases.

As for near-term expectations, investors will monitor not just the revenue trajectory but the trajectory of EPS signals and any explicit earnings surprise relative to a forthcoming EPS consensus. Butterfly’s current trajectory implies that the upcoming quarterly updates—where the revenue forecast is reconciled with actual profitability—will shape how this story is valued versus pure hardware peers.

Industry outlook and potential risks

The move toward embedded AI and federal-government exposure brings both upside and risk. Execution depends on managing partnerships, maintaining data and regulatory compliance across multiple jurisdictions, and sustaining hardware sales while scaling a software-first revenue base. The sector will likely watch Butterfly’s progress on profitability milestones as its software and services mix matures, with attention to whether the earnings surprise risk remains manageable as guidance shifts.

Bottom line

Butterfly Network is executing a growth plan that tilts toward embedded software, AI-enabled applications, and global expansion. The Q2 2026 results show meaningful top-line momentum and a clearer path to monetizing an ecosystem around Ultrasound-on-Chip, even as near-term profitability remains a work in progress. For investors, the implications extend beyond Butterfly itself: a more integrated hardware-software model in medical devices could recalibrate expectations for margins, sales cycles, and government-enabled revenue streams across the sector.